ClinicalTrials.gg
Active, not recruitingNCT05367440PETRANHAUpdated Aug 26, 2026

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

A Phase 1/2 interventional study of AZD5305 and Enzalutamide in Metastatic Prostate Cancer, sponsored by AstraZeneca. Active, not recruiting at 20 sites in 4 countries. Open to male participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
174
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.

Enrollment
20th of 70
174 · median 81
Started
2022
with 2 others
Phase 1/2
2 of 70
none open now
Primary completion
2031-04
later than 34 of 35 live
Registered
59th of 70
by date

Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 20th largest by enrollment, is one of 3 that started in 2022, is one of 2 in phase 1/2, reaches primary completion later than 34 of the 35 other live ones, and was the 59th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apalutamide

apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 130 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing apalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.

Read the detailed description

The study consists of 2 parts, Part A and Part B. Part A consists of the dose escalation cohorts and will include patients with metastatic castration resistant prostate cancer (mCRPC) or metastatic castration-sensitive prostate cancer (mCSPC); Part B consists of dose expansion cohorts and will include patients with mCSPC only.

Part A comprises 4 individual arms each evaluating the safety, tolerability, and preliminary efficacy of AZD5305 in combination with a specific new hormonal agent (NHA). Part B comprises up to 4 individual arms (arms to be opened at Sponsor's discretion) each investigating the preliminary efficacy and aims to further build on the safety data for the combination of AZD5305 with a specific NHA.

Approximately 783 patients will be enrolled and screened to ensure the required number of evaluable patients in each part and arm are enrolled. For Part A, 356 patients may be screened to obtain up to approximately 308 patients that can be assigned to study treatments across all study arms (1 to 4). For Part B dose expansion cohorts, up to 427 patients may be screened to obtain up to approximately 360 patients that can be assigned to study treatments across all study arms (1 to 4).

Study treatment administration will continue until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment occur.

03

Conditions studied

  • Metastatic Prostate Cancer

Browse trials for

Keywords

  • PETRANHA
  • AZD5305
  • New Hormonal Agents
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For whole study:

  • Age ≥ 18 at the time of screening.
  • confirmed diagnosis of prostate cancer.
  • Candidate for treatment with enzalutamide, abiraterone acetate, darolutamide or apalutamide with documented current evidence of metastatic prostate cancer.
  • Surgically or medically castrated.
  • Adequate organ and marrow function.
  • Performance Status (ECOG PS): 0-1 with no deterioration over the previous 2 weeks.
  • ≥ 16 weeks.
  • Non-sterilized male patients who are sexually active with a female partner of must use a condom with spermicide from screening to approximately 6 months after the last dose of study treatment .

For Patients Recruited Specifically to tumour Pharmacodynamic Cohorts:

  • Patients must have at least 1 tumour suitable for paired

For Part A:

  • Patients with Metastatic Castrate ion-Resistant Prostate Cancer (mCRPC) or Metastatic Castration Sensitive Prostate Cancer (mCSPC).

For Part B:

  • Patients must have mCSPC (de novo or recurrent) with a baseline PSA value of ≥ 0.2 ng/mL

Exclusion criteria

Exclusion Criteria:

For Part A mCRPC patients only:

  • Any previous treatment with a new hormonal agent (NHA), poly (adenosine diphosphateribose) polymerase inhibitor (PARPi), Lutetium prostate-specific membrane antigen (Lu-PSMA), platinum chemotherapy
  • Patients recruited to the PDc cohorts should not have received a prior use of new hormonal agents (NHA).

For Part A and Part B mCSPC Patients:

  • Any previous treatment with a PARPi, platinum, NHA, Immuno-oncology (IO), radiopharmaceutical therapy, or prior treatment with docetaxel in mCSPC setting.
  • Concomitant use of medications or herbal supplements known to be:

    1. Strong and moderate inducers/inhibitors (applies for all arms)
    2. For Arm 1 (enzalutamide) patients: Strong CYP2C8 inhibitors
    3. For Arm 3 (darolutamide) patients: Strong P-glycoprotein inducers
  • Concomitant use of drugs that are known to prolong or shorten and have a known risk of Torsades de Pointes.
  • Treatment with any of the following:

    1. Any agents or study interventions from a previous clinical study within 5 half lives or 3 weeks (whichever is longer) of the first dose of study treatment.
    2. Any other anticancer treatment within the following time periods prior to the first dose of study treatment: (i) Cytotoxic and non-cytotoxic treatment: 3 weeks or 5 half-lives (whichever is shorter). (ii) Biological products including immuno-oncology agents: 4 weeks before enrolment.
    3. Any live virus or bacterial vaccine within 28 days of the first dose of study treatment.
  • Any concurrent anticancer therapy or concurrent use of prohibited medications.
  • Major surgery within 4 weeks prior to the first dose of study treatment.
  • Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study treatment.
  • With the exception of alopecia, and peripheral neuropathy; any unresolved toxicities from prior therapy greater than (CTCAE) Grade 1 at the time of study enrolment.
  • Any history of persisting (> 2 weeks) severe pancytopenia.
  • Spinal cord compression, or unless asymptomatic and treated and stable.
  • Any evidence of severe or uncontrolled systemic diseases, including, active bleeding diatheses, or active infection including , and (HIV).
  • Patients with any known predisposition to bleeding (eg, active peptic ulceration, recent [within 6 months] haemorrhagic stroke, proliferative diabetic retinopathy.
  • Any cardiac disorders including QT prolongation, abnormal (ECG).
  • Any clinically significant cardiovascular diseases including symptomatic heart failure, uncontrolled hypertension, acute coronary syndrome, cardiomyopathy, valvular heart disease, atrial fibrillation, stroke.
  • Patients with history of myelodysplastic syndrome (MDS)/ acute myeloid leukaemia (AML).
  • nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection.
  • Known allergy or to investigational product(s) or any of the of the investigational product(s).
  • Any condition that would interfere with evaluation of the study treatment or interpretation of patient safety or study results.
  • Uncontrolled intercurrent illness within the last 12 months, including but not limited to, active interstitial lung disease, serious chronic gastrointestinal (GI) conditions associated with diarrhoea, or psychiatric illness/social situations
  • History of another primary except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study treatment and of low potential risk for recurrence.
  • Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
  • Arm 1 (Enzalutamide) and Arm 4 (Apalutamide): History of seizure or any condition that may predispose to seizure (eg, prior cortical stroke, significant brain trauma).
  • Arm 2 (Abiraterone acetate) only: (i) Active infection or other medical condition that would contraindicate the use of systemic (prednisone/prednisolone). (ii) Low serum potassium (\< 3.5 mmol/L). (iii) History of uncontrolled pituitary or adrenal dysfunction.
  • Arm 4 (Apalutamide): (i) Moderate or severe skin conditions or diseases that could affect the skin (eg. scleroderma, lupus). (ii) Any skin or medical condition that in the Investigator's opinion could increase the risk of skin toxicity.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
174 participants (actual)

Study arms

  • Experimental
    Arm 1 (AZD5305 in combination with enzalutamide)

    Patients will receive an oral dose of AZD5305 and Enzalutamide once daily until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment occur.

    Drug: AZD5305 · Drug: Enzalutamide

  • Experimental
    Arm 2 (AZD5305 in combination with abiraterone acetate)

    Patients will receive an oral dose of AZD5305 and Abiraterone Acetate once daily until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment occur.

    Drug: AZD5305 · Drug: Abiraterone Acetate

  • Experimental
    Arm 3 (AZD5305 in combination with darolutamide)

    Patients will receive an oral dose of AZD5305 once daily and Darolutamide twice daily until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment occur.

    Drug: AZD5305 · Drug: Darolutamide

  • Experimental
    Arm 4 (AZD5305 in combination with apalutamide)

    Patients will receive an oral dose of AZD5305 and Apalutamide once daily until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment occur.

    Drug: Apalutamide

Interventions

  • Patients will receive an oral dose of AZD5305 once daily

  • Patients will receive an oral dose of Enzalutamide once daily

    Also known as: Xtandi

  • Patients will receive an oral dose of Abiraterone Acetate once daily

    Also known as: Zytiga

  • Patients will receive an oral dose of Darolutamide twice daily

    Also known as: Nubeqa

  • Patients will receive an oral dose of Apalutamide once daily

    Also known as: Erleada

06

What researchers measure

Primary outcomes

  1. Number of patients with Adverse Events and Serious Adverse Events

    Number of patients with adverse events and with serious adverse events including abnormal clinical observations, abnormal ECG parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline will be assessed.

    Time frame: Up to post treatment follow-up (28 days after last dose) [assessed up to 2.3 years]

  2. Part A: Number of patients with Dose Limiting Toxicities (DLTs)

    To assess the safety and tolerability of AZD5305 when given in combination with NHA.

    Time frame: For Arm 1: 35 days, For Arm 2 and 3: 28 days

Secondary outcomes

  1. Area Under the concentration Curve (AUC) of AZD5305

    To characterise the PK (AUC) of AZD5305 at steady state after multiple dosing of AZD5305 monotherapy.

    Time frame: At the end of Cycle 0 (Cycle 0 is of 7 days)

  2. Maximum plasma concentration (Cmax) of AZD5305

    To characterise the PK (Cmax) of AZD5305 at steady state after multiple dosing of AZD5305 monotherapy.

    Time frame: At the end of Cycle 0 (Cycle 0 is of 7 days)

  3. Time to maximum concentration (tmax) of AZD5305

    To characterise the PK (tmax) of AZD5305 at steady state after multiple dosing of AZD5305 monotherapy.

    Time frame: At the end of Cycle 0 (Cycle 0 is of 7 days)

  4. AUC of AZD5305

    To characterise the PK (AUC) of AZD5305 following oral dose administration of AZD5305 in combination with NHA.

    Time frame: Arm 1: At Cycle 1 Day 1, Cycle 1 Day 22, Cycle 2 Day 1, Cycle 2 Day 2, Cycle 2 Day 8, and Cycle 3 Day 1; Arm 2 and 3: At Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 2 Day 1 (Each Cycle is of 28 days)

  5. Cmax of AZD5305

    To characterise the PK (Cmax) of AZD5305 following oral dose administration of AZD5305 in combination with NHA.

    Time frame: Arm 1: At Cycle 1 Day 1, Cycle 1 Day 22, Cycle 2 Day 1, Cycle 2 Day 2, Cycle 2 Day 8, and Cycle 3 Day 1; Arm 2 and 3: At Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 2 Day 1 (Each Cycle is of 28 days)

  6. tmax of AZD5305

    To characterise the PK (tmax) of AZD5305 following oral dose administration of AZD5305 in combination with NHA.

    Time frame: Arm 1: At Cycle 1 Day 1, Cycle 1 Day 22, Cycle 2 Day 1, Cycle 2 Day 2, Cycle 2 Day 8, and Cycle 3 Day 1; Arm 2 and 3: At Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 2 Day 1 (Each Cycle is of 28 days)

  7. Objective response rate (ORR)

    To assess the preliminary antitumour activity of AZD5305 in combination with NHA. ORR will be assessed as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (soft tissue) and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) and is defined as the percentage of patients who have a confirmed visit response of complete response (CR) or partial response (PR) in their soft tissue disease and no disease progression in their bone scan.

    Time frame: From Screening (Day -28) to confirmed disease progression [assessed up to 2.3 years]

  8. Duration of response (DoR)

    To assess the preliminary antitumour activity of AZD5305 in combination with NHA. DoR is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression or death in the absence of progressive disease (PD).

    Time frame: From Screening (Day -28) to confirmed disease progression [assessed up to 2.3 years]

  9. Time to response (TTR)

    To assess the preliminary antitumour activity of AZD5305 in combination with NHA. TTR is defined as the time from first dose until the first documentation of a subsequently confirmed objective response.

    Time frame: From Screening (Day -28) to confirmed disease progression [assessed up to 2.3 years]

  10. Radiographic progression-free survival (rPFS)

    To assess the preliminary antitumour activity of AZD5305 in combination with NHA. rPFS is defined as the time from start of first treatment until progression as per RECIST v1.1 (soft tissue) and PCWG3 criteria (bone) or death from any cause.

    Time frame: From Screening (Day -28), 12 months, 24 months and up to confirmed disease progression [assessed up to 2.3 years]

  11. Percentage change in tumour size

    To assess the preliminary antitumour activity of AZD5305 in combination with NHA. Percentage change in tumour size will be determined for patients with measurable disease at baseline.

    Time frame: From Screening (Day -28) to confirmed disease progression [assessed up to 2.3 years]

  12. Number of patients with ≥ 50% prostate-specific antigen (PSA) decrease from baseline

    To assess the preliminary antitumour activity of AZD5305 in combination with NHA.

    Time frame: From Screening (Day -28) to confirmed disease progression [assessed up to 2.3 years]

  13. Number of patients with ≥ 90% prostate-specific antigen (PSA) decrease from baseline

    To assess the preliminary antitumour activity of AZD5305 in combination with NHA.

    Time frame: From Screening (Day -28) to confirmed disease progression [assessed up to 2.3 years]

  14. Part B: Number of patients with undetectable PSA (< 0.2 ng/mL)

    To assess the preliminary antitumour activity of AZD5305 in combination with NHA.

    Time frame: 3, 6, 9 and 12 months

  15. PSA Progression-free survival

    To assess the preliminary antitumour activity of AZD5305 in combination with NHA.

    Time frame: 6, 12, 18, 24 and 30 months

  16. AUC of Enzalutamide

    To characterize the PK (AUC) of Enzalutamide in plasma at steady state when given orally in combination with AZD5305

    Time frame: At Cycle 1 Day 22, Cycle 2 Day 1, Cycle 2 Day 2, Cycle 2 Day 8 and Cycle 3 Day 1 (Each Cycle is of 28 days)

  17. Cmax of Enzalutamide

    To characterize the PK (Cmax) of Enzalutamide in plasma at steady state when given orally in combination with AZD5305

    Time frame: At Cycle 1 Day 22, Cycle 2 Day 1, Cycle 2 Day 2, Cycle 2 Day 8 and Cycle 3 Day 1 (Each Cycle is of 28 days)

  18. tmax of Enzalutamide

    To characterize the PK (tmax) of Enzalutamide in plasma at steady state when given orally in combination with AZD5305

    Time frame: At Cycle 1 Day 22, Cycle 2 Day 1, Cycle 2 Day 2, Cycle 2 Day 8 and Cycle 3 Day 1 (Each Cycle is of 28 days)

  19. AUC of Apalutamide

    To characterize the PK (AUC) of Apalutamide in plasma at steady state when given orally in combination with AZD5305

    Time frame: At Cycle 1 Day 22, Cycle 2 Day 1, Cycle 2 Day 2, Cycle 2 Day 8 and Cycle 3 Day 1 (Each Cycle is of 28 days)

  20. Cmax of Apalutamide

    To characterize the PK (Cmax) of Apalutamide in plasma at steady state when given orally in combination with AZD5305

    Time frame: At Cycle 1 Day 22, Cycle 2 Day 1, Cycle 2 Day 2, Cycle 2 Day 8 and Cycle 3 Day 1 (Each Cycle is of 28 days)

  21. tmax of Apalutamide

    To characterize the PK (tmax) of Apalutamide in plasma at steady state when given orally in combination with AZD5305

    Time frame: At Cycle 1 Day 22, Cycle 2 Day 1, Cycle 2 Day 2, Cycle 2 Day 8 and Cycle 3 Day 1 (Each Cycle is of 28 days)

  22. Part B: Homologous recombination repair gene mutation (HRRRm)

    To investigate HRRm (including BRCA1/2) and their relationship with clinical response

    Time frame: From Screening (Day -28) to confirmed disease progression [assessed up to 2.3 years]

07

Study locations

20 sites
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Syracuse, New York 13210, United States
  • Research Site
    Myrtle Beach, South Carolina 29572, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Houston, Texas 77094, United States
  • Research Site
    Camperdown, 2050, Australia
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    East Melbourne, 3002, Australia
  • Research Site
    Heidelberg, 3084, Australia
  • Research Site
    Melbourne, 3004, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Candiolo, 10060, Italy
  • Research Site
    Milan, 20133, Italy
  • Research Site
    Orbassano, 10043, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
  • Research Site
    Glasgow, G12 0YN, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Plymouth, PL6 8DH, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Apr 2031, 106 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 106 months is above that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2022
First posted
May 10, 2022
StartActual
Jun 2, 2022
Primary completionEst.
Apr 11, 2031
CompletionEst.
Apr 11, 2031
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05367440
Lead sponsor
AstraZeneca
Collaborators
Bayer
Responsible party
Sponsor
First posted
May 10, 2022
Start date
Jun 2, 2022
Primary completion
Apr 11, 2031 (estimated)
Completion
Apr 11, 2031 (estimated)
Last update
Aug 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD5305 · Apalutamide

Start the discussion